

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Xyrem (sodium oxybate) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Xyrem (sodium oxybate).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: <u>1-866-331-2104</u>]. If you have any questions or concerns, please call <u>1-866-331-2103</u>. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at:** http://www.providers.kaiserpermanente.org/mas/formulary.html

1 – Patient Information				
Patient Name:	Kaiser Medical ID#:	Date of Birth:		
2 – Prescriber Information				
Is the prescriber a pulmonologist (sleep s	pecialist) or neurologist? No Yes			
If consulted with a specialist, specialist na	ame and specialty:			
Prescriber Name:	Specialty:	NPI:		
Prescriber Address:				
Prescriber Phone #:	Prescriber Fax #:			
Please check the boxes that apply: □ Initial Request □ Continuation of Ther	apy Request			
	3 – Pharmacy Information			
Pharmacy Name:	Pharmacy NPI:			
Pharmacy Phone #	Pharmacy Fax #:			
	4 – Drug Therapy Requested			

5- Diagnosis/Clinical Criteria

	1.	Is this request for initial or continuing therapy?			
		☐ Initial therapy ☐ Continu	uing therapy, State date:		
	1.	Member has enrolled in Xyrem Patient Success Program? AND □ No □ Yes			
		eatment of excessive daytime sleepiness in narcolepsy: Member has diagnosis of excessive daytime sleepiness in narcolepsy AND □ No □ Yes			
	3.	Member has had an adequate trial (≥2 months) of a preferred stimulant (methylphenidate, amphetamine salt combination, dextroamphetamine) AND modafinil/armodafinil, unless contraindicated AND □ No □ Yes			
	4.	. Member has had Adequate trial of Sunosi (≥2 months) AND Wakix (≥2 months), unless contraindicated AND □ No □ Yes			
	5.	. Member is 7 years to 65 years of age AND □ No □ Yes			
	6.	Member is not on any sedative-hypnotic agents, opioids, benzodiazepines, or alcohol AND \Box No \Box Yes			
	7.	Member has had adequate trial (≥2 months) of Xywav? □ No □ Yes			
	Treatment of cataplexy due to narcolepsy:				
	8.	Member has diagnosis of cataplexy due to narcolepsy AND □ No □ Yes			
	9.	 Member has had an adequate trial (≥2 m contraindication AND No □ Yes 	onths) of at least 2 of the following: TCAs, SSRI, or SNRI or there is a		
	10.	O. Patient has had adequate trial (≥2 month□ No □ Yes	s) of Xywav?		
For	For continuation of therapy, please respond to additional questions below:				
	1.	. Does the member have documentation o □ No □ Yes	f positive clinical response to therapy? AND		
	2.	. Has the member continued to be under t □ No □ Yes	he care of a specialist? AND		

7 – Prescriber Sign-Off

Additional Information -

- 1. Please submit chart notes/medical records for the patient that are applicable to this request.
- 2. If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:

I certify that the information provided is accurate. Supporting documentation is available for State audits.				
Prescriber Signature:	Date:			
Please Note: This document contains confidential information, including protected health inf private and legally protected by law, including HIPAA. If you are not the intended recipient, y any action in reliance on the contents of this telecopied information is strictly prohibited. Pl	ou are hereby notified that any disclosure, copying, distribution or taking of			